Recent News

• 05.07.2025 - Veracyte First Quarter 2025 Financial Results Webcast
• 04.25.2025 - Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
• 04.22.2025 - Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
• 04.21.2025 - Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
• 04.16.2025 - Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
• 04.02.2025 - Bill Bonello
• 03.25.2025 - New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer
• 03.19.2025 - Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25
• 03.11.2025 - Leerink Partners Global Healthcare Conference

Recent Filings

• 04.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.07.2025 - 144 Report of proposed sale of securities
• 03.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.06.2025 - 4 Statement of changes in beneficial ownership of securities